This transcript has been edited for clarity. Vallerie McLaughlin, MD: Hello, and welcome to this podcast series. I'm Dr Vallerie McLaughlin, the Kim A. Eagle Endowed Professor of Cardiovascular ...
Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “From 2012, our team and other teams have provided some ...
Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...
In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this report, we follow up on what has happened since. After the FDA approved both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results